Clinical trial Recruiting at 1 site Early Phase 1 Interventional Ages 18 to 65

Collagen Mesotherapy for Chronic Low Back Pain in the Lumbosacral Region

Official title: Evaluation of the Effectiveness and Safety of Mesotherapy in the Treatment of Chronic Low Back Pain Syndrome: a Randomized Study

Run by National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · NCT07675304 · Data updated 2026-11-12

This study tests whether collagen mesotherapy, with or without lidocaine, can reduce pain and improve function in adults with chronic non-specific low back pain localized to the lumbosacral area.

More Chronic Non-specific Low Back Pain trials

Quick facts

PhaseEarly Phase 1
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment90 (estimated)
SponsorNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland
Research network
Drugs / interventionsradiation
Locations1 site (Warsaw)
StatusRecruiting
StartedMay 6, 2026
Main results expectedDecember 2026
Study endsMarch 2027
Registry record updatedJune 30, 2026
Trial IDNCT07675304 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18-65 with chronic non-specific localized low back pain in the lumbosacral region, without radicular symptoms, and recent imaging confirming the diagnosis.

Probably not a fit

Patients with allergies to collagen or lidocaine, active infection or skin lesions at the injection site, autoimmune disease, or other exclusion criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with chronic non-specific low back pain will be randomized to receive five weekly mesotherapy sessions in the paraspinal area, using either type I tropocollagen, 1% lidocaine, or a combination. Each session involves about 20 intradermal injections of 0.1 mL into the lumbosacral soft tissues, and outcomes will be measured for pain, function, and spine mobility. The study aims to compare the effectiveness and safety of collagen alone, lidocaine alone, and their combination over the treatment course. The trial is conducted at the National Institute of Geriatrics, Rheumatology and Rehabilitation in Warsaw, Poland, under a parallel-group design. Participants must be adults 18-65 years old with chronic localized lumbosacral pain and recent imaging confirming the diagnosis.

Why it matters

Potential benefit: If successful, patients could experience reduced pain and improved mobility, potentially enhancing quality of life and ability to participate in physical therapy.

How similar studies have gone: Prior approaches using intra- or intradermal collagen-based interventions have shown mixed results; this study tests a novel head-to-head comparison with lidocaine and their combination in CLBP.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Age between 18 and 65 years Chronic localized pain in the lumbosacral spine without radicular symptoms or radiation to the lower limbs Recent spinal imaging (X-ray, computed tomography (CT), or magnetic resonance imaging (MRI)) performed within the last 6 months confirming the diagnosis

Exclusion Criteria:

Known allergy to collagen or lignocaine Active malignancy Autoimmune diseases Skin lesions in the lumbosacral region Active infection Lack of informed consent

Where it's running

  • National Institute of Geriatrics, Rheumatology and Rehabilitation
    Warsaw, Poland
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.